Subcutaneous transplantation of human embryonic stem cells-derived pituitary organoids.
ACTH
organoid
pituitary
regenerative medicine
subcutaneous transplantation
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
23
12
2022
accepted:
13
02
2023
entrez:
20
3
2023
pubmed:
21
3
2023
medline:
22
3
2023
Statut:
epublish
Résumé
The pituitary gland, regulating various hormones, is central in the endocrine system. As spontaneous recovery from hypopituitarism is rare, and exogenous-hormone substitution is clumsy, pituitary replacement hESC-derived POs were transplanted into inguinal subcutaneous white adipose tissue (ISWAT) and beneath dorsal skin, a relatively avascular region (AR), of hypophysectomized severe combined immunodeficient (SCID) mice. Pituitary function was evaluated thereafter for ¾ 6mo, assaying basal plasma ACTH and ACTH response to corticotropin-releasing hormone (CRH) stimulation. Histopathologic examination of organoids 150d after transplantation assessed engraftment. Some mice received an inhibitor of vascular endothelial growth factor (VEGF) to permit assessment of how angiogenesis contributed to subcutaneous engraftment. During follow-up, both basal and CRH-stimulated plasma ACTH levels were significantly higher in the ISWAT group ( Subcutaneous transplantation of hESC-derived POs into hypopituitary SCID mice efficaciously renders recipients ACTH-sufficient.
Identifiants
pubmed: 36936140
doi: 10.3389/fendo.2023.1130465
pmc: PMC10018142
doi:
Substances chimiques
Vascular Endothelial Growth Factor A
0
Adrenocorticotropic Hormone
9002-60-2
Corticotropin-Releasing Hormone
9015-71-8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1130465Informations de copyright
Copyright © 2023 Sasaki, Suga, Takeuchi, Nagata, Harada, Kondo, Ito, Maeda, Sakakibara, Soen, Miwata, Asano, Ozaki, Taga, Kuwahara, Nakano, Arima and Saito.
Déclaration de conflit d'intérêts
ST and AK are employed by Sumitomo Pharma. TN is employed by Sumitomo Chemical. HSu has received research funding from Sumitomo Pharma and Sumitomo Chemical. Authors are co-inventors on patent applications related to the study presented in this article. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest.
Références
Cell Stem Cell. 2021 Dec 2;28(12):2047-2061.e5
pubmed: 34861146
Transplantation. 2018 Mar;102(3):387-395
pubmed: 29019814
Lancet. 2007 Apr 28;369(9571):1461-1470
pubmed: 17467517
Cell Rep Med. 2021 Dec 02;2(12):100466
pubmed: 35028608
Nature. 2011 May 19;473(7347):298-307
pubmed: 21593862
Nature. 2011 Nov 09;480(7375):57-62
pubmed: 22080957
Endocrinology. 1964 Feb;74:301-3
pubmed: 14122540
J Clin Endocrinol Metab. 1996 Dec;81(12):4358-65
pubmed: 8954042
Endocrine. 2014 Sep;47(1):198-205
pubmed: 24366641
Hepatology. 2022 Sep;76(3):660-675
pubmed: 34940991
J Clin Endocrinol Metab. 2015 Feb;100(2):407-16
pubmed: 25419882
Exp Anim. 2011;60(5):481-7
pubmed: 22041285
Transplantation. 2018 Jun;102(6):945-952
pubmed: 29521877
Eur J Endocrinol. 2018 Sep;179(3):R151-R163
pubmed: 29880706
N Engl J Med. 1989 Dec 28;321(26):1797-803
pubmed: 2687691
Cell Stem Cell. 2008 Nov 6;3(5):519-32
pubmed: 18983967
Nat Biotechnol. 2015 May;33(5):518-23
pubmed: 25893782
Nat Rev Endocrinol. 2021 Feb;17(2):114-129
pubmed: 33247226
Cell Rep. 2020 Jan 7;30(1):18-24.e5
pubmed: 31914385
Endocr Pathol. 2005 Spring;16(1):67-73
pubmed: 16000849
Cell Stem Cell. 2019 Apr 4;24(4):566-578.e7
pubmed: 30853558
Cell Rep. 2014 May 22;7(4):1298-1309
pubmed: 24835994
Transplantation. 2020 Dec;104(12):2516-2527
pubmed: 33215898
Stem Cell Reports. 2015 Mar 10;4(3):360-73
pubmed: 25684226
Nat Commun. 2016 Jan 14;7:10351
pubmed: 26762480
Proc Natl Acad Sci U S A. 1998 May 12;95(10):5672-7
pubmed: 9576942